Docoh
Loading...

ARIA ARIAD Pharmaceuticals

ARIAD is a global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. Our mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest unmet medical need – aggressive cancers where current therapies are inadequate. We are focused on value-driving investments in commercialization, research and development, and new business development initiatives that we expect will lead to sustained profitability and increased shareholder value. As described in further detail below, we are currently commercializing or developing the following three products and product candidates:

Company profile

Ticker
ARIA
Exchange
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
223106987

Calendar

12 Feb 17
5 Dec 21
31 Dec 21
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
12 Oct 21 Takeda Pharmaceutical Common Stock Conversion Acquire C Yes No 0 1,615,427 0 1,615,427
12 Oct 21 Takeda Pharmaceutical Series A Preferred Stock Common Stock Conversion Dispose C Yes No 0 1,615,427 0 0

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: approach, avoid, Bernard, Congressional, cooperate, cooperating, Copenhagen, distraction, driven, Elijah, ESMO, estate, improper, inquired, inquiry, leasehold, legislative, PDUFA, plant, PMDA, poster, preclude, Prescription, real, relapsed, Rep, scrutiny, Sen, Society, statute, subpoena, thousand, User
Removed: accommodate, adult, appointment, area, attract, built, conducting, contemplated, contract, delayed, dependent, difficult, domestic, eastern, effectively, expansion, experience, experienced, fail, hand, inadequate, influence, intense, international, investigational, joint, living, local, locally, natural, occlusive, occupancy, organization, pool, President, production, proposed, randomized, relocate, respond, retain, separation, size, skilled, subsequently, suffer, target, technical, TKI, trained, transforming, tyrosine, uncertainty, unexpected, validation, vi, vii

Patents

GRANT
Utility
Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
23 Nov 21
Inventors: Wei-Sheng Huang, Yun Zhang, Willmen Youngsaye, Xiaotian Zhu, Erin Geno
APP
Utility
Crystalline Forms of 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] Phenyl} PYRIMIDINE-2,4-DIAMINE
18 Nov 21
Novel crystalline forms of brigatinib, pharmaceutical compositions comprising the same, and methods of their preparation and use of the same are disclosed herein.
APP
Utility
Crystalline Forms of 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE and Its Mono Hydrochloride Salt
4 Nov 21
Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
APP
Utility
Heteroaryl Compounds for Kinase Inhibition
21 Oct 21
Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFRand mutant HER2 activity, are described herein.
GRANT
Utility
Benzimidazole compounds as c-Kit inhibitors
14 Sep 21
Inventors: Nicholas E. Bencivenga, David C. Dalgarno, Joseph M. Gozgit, Wei-Sheng Huang, Anna Kohlmann, Feng Li, Jiwei Qi, William C. Shakespeare, Ranny M. Thomas, Yihan Wang, Yun Zhang, Xiaotian Zhu